Lifyorli (copackaged)
(Relacorilant)Phase 3Small molecule
Lifyorli (copackaged) is a small molecule that works as a Glucocorticoid Receptor Antagonist.[2] It is being investigated across 7 indications, with its most advanced program in Phase 3.[1]
Lifyorli (copackaged) is one of 178 small molecule programs targeting Alcohol Dependence. It is currently in Phase 3.
7
Indications
20
Total Trials
7
Active Trials
177
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
10
Patents
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
348 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Talzenna
PfizerPhase 3
Glucophage
EMD SeronoPhase 3
Lifyorli (copackaged)
CCorcept Therapeutics
Phase 3
Xaluritamig
AmgenPhase 3
AAA617
NovartisPhase 3
Radium-223
BayerPhase 3
Triptorelin Embonate
IpsenPhase 3
Androgen Deprivation Treatment
MMedical University of Vienna
Phase 3
Trexall
Jazz PharmaceuticalsPreclinical
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Prostate Cancer2 trials
Cushing syndrome2 trials
Cardiac Repolarization1 trial
Tics1 trial
10 more indications
Primary Peritoneal Cancer1 trial
Primary Peritoneal1 trial
Adenoma1 trial
Nab-paclitaxel1 trial
Hepatic Impairment1 trial
Oral1 trial
Adenocarcinoma1 trial
Recurrent or Metastatic Cervical Cancer1 trial
Ovarian Cancer1 trial
Unspecified4 trials
Regulatory
FDA Approval Timeline[4]
Mar 25, 2026
LIFYORLI (COPACKAGED)
NDA NDA220641
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Relacorilant. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Glucocorticoid Receptor Antagonist[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- CCorcept Therapeutics